Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Voss

Showing results (11-20 of 141) with videos related to

Pageof 15
Sort By:
Annals of Translational Medicine|December 14, 2020
Prognostic models in papillary renal cell carcinomaKyrollis Attalla, Martin H Voss, A Ari Hakimi
Nature Reviews. Urology|April 8, 2026
From diversity to function: microbiome precision in RCCAntonio Ocejo, Ritesh R Kotecha, Martin H Voss
Hematology/Oncology Clinics of North America|July 19, 2011
mTOR inhibitors in advanced renal cell carcinomaMartin H Voss, Ana M Molina, Robert J Motzer
Expert Review of Anticancer Therapy|August 3, 2011
High-dose chemotherapy and stem cell transplantation for advanced testicular cancerMartin H Voss, Darren R Feldman, Robert J Motzer
Oncology (Williston Park, N.Y.)|January 4, 2018
Optimizing Treatment Approaches in Advanced Renal CancerJuan C Osorio, Robert J Motzer, Martin H Voss
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinomaMartin H Voss, James J Hsieh, Robert J Motzer
Nature Reviews. Clinical Oncology|April 27, 2019
Author Correction: Towards individualized therapy for metastatic renal cell carcinomaRitesh R Kotecha, Robert J Motzer, Martin H Voss
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor InhibitorsAlison M Schram, Martin H Voss, David M Hyman
Nature Reviews. Urology|June 22, 2016
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinomaMaria I Carlo, Martin H Voss, Robert J Motzer
Nature Reviews. Clinical Oncology|April 18, 2019
Towards individualized therapy for metastatic renal cell carcinomaRitesh R Kotecha, Robert J Motzer, Martin H Voss
Pageof 15

Showing results (11-20 of 141) with videos related to

Sort By:
Pageof 15
Annals of Translational Medicine|December 14, 2020
Prognostic models in papillary renal cell carcinomaKyrollis Attalla, Martin H Voss, A Ari Hakimi
Nature Reviews. Urology|April 8, 2026
From diversity to function: microbiome precision in RCCAntonio Ocejo, Ritesh R Kotecha, Martin H Voss
Hematology/Oncology Clinics of North America|July 19, 2011
mTOR inhibitors in advanced renal cell carcinomaMartin H Voss, Ana M Molina, Robert J Motzer
Expert Review of Anticancer Therapy|August 3, 2011
High-dose chemotherapy and stem cell transplantation for advanced testicular cancerMartin H Voss, Darren R Feldman, Robert J Motzer
Oncology (Williston Park, N.Y.)|January 4, 2018
Optimizing Treatment Approaches in Advanced Renal CancerJuan C Osorio, Robert J Motzer, Martin H Voss
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinomaMartin H Voss, James J Hsieh, Robert J Motzer
Nature Reviews. Clinical Oncology|April 27, 2019
Author Correction: Towards individualized therapy for metastatic renal cell carcinomaRitesh R Kotecha, Robert J Motzer, Martin H Voss
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor InhibitorsAlison M Schram, Martin H Voss, David M Hyman
Nature Reviews. Urology|June 22, 2016
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinomaMaria I Carlo, Martin H Voss, Robert J Motzer
Nature Reviews. Clinical Oncology|April 18, 2019
Towards individualized therapy for metastatic renal cell carcinomaRitesh R Kotecha, Robert J Motzer, Martin H Voss
Pageof 15